SOPHiA GENETICS (NASDAQ:SOPH) Trading 2.8% Higher – What’s Next?

Shares of SOPHiA GENETICS SA (NASDAQ:SOPH) shot up 2.8% during mid-day trading on Friday . The company traded as high as $4.75 and last traded at $4.73. 45,371 shares traded hands during trading, a decline of 38% from the average session volume of 73,308 shares. The stock had previously closed at $4.60.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. BTIG Research lifted their price target on SOPHiA GENETICS from $6.00 to $7.00 and gave the company a “buy” rating in a research note on Monday, November 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Wednesday, October 8th. Finally, Wall Street Zen upgraded shares of SOPHiA GENETICS to a “hold” rating in a research report on Saturday, November 1st. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $7.00.

SOPHiA GENETICS Price Performance

The firm has a market capitalization of $319.65 million, a P/E ratio of -10.28 and a beta of 1.10. The company has a fifty day moving average of $4.59 and a 200 day moving average of $3.87. The company has a debt-to-equity ratio of 0.78, a current ratio of 2.80 and a quick ratio of 2.62.

SOPHiA GENETICS (NASDAQ:SOPH) last released its quarterly earnings results on Tuesday, November 4th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.10). SOPHiA GENETICS had a negative return on equity of 37.75% and a negative net margin of 41.13%.The firm had revenue of $19.46 million for the quarter, compared to the consensus estimate of $18.13 million. Sell-side analysts predict that SOPHiA GENETICS SA will post -0.96 earnings per share for the current year.

Institutional Trading of SOPHiA GENETICS

Large investors have recently bought and sold shares of the business. Savvy Advisors Inc. acquired a new position in shares of SOPHiA GENETICS in the 3rd quarter valued at about $48,000. Squarepoint Ops LLC acquired a new stake in SOPHiA GENETICS during the third quarter worth approximately $49,000. GSA Capital Partners LLP bought a new stake in SOPHiA GENETICS in the third quarter worth approximately $59,000. Susquehanna International Group LLP acquired a new position in SOPHiA GENETICS in the third quarter valued at approximately $88,000. Finally, Silverberg Bernstein Capital Management LLC boosted its holdings in shares of SOPHiA GENETICS by 31.8% during the 2nd quarter. Silverberg Bernstein Capital Management LLC now owns 45,715 shares of the company’s stock worth $142,000 after buying an additional 11,040 shares in the last quarter. 31.59% of the stock is currently owned by institutional investors and hedge funds.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.